Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT Application Duration in Cutaneous Carcinomas
NCT00002975Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Feb 1997
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 5-aminolevulinic acid in basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and actinic keratosis (AK) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Response Rate at 1 year. Started Feb 1997; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
basal cell carcinoma (BCC)squamous cell carcinoma (SCC)actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00002975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002975.